A Phase 4 interventional study of Infliximab and Infliximab in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW. Recruiting at 15 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-26.
Sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing infliximab in Inflammatory Bowel Diseases — 6 open to participants now, 7 under way, none of them phase 3. Infliximab · Inflammatory Bowel Diseases.
Among the 20 studies testing infliximab in Inflammatory Bowel Diseases, this one is the 3rd largest by planned enrollment, is the only one that started in 2024, is one of 10 in phase 4, and was the 17th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →6 of the 20 studies testing infliximab in Inflammatory Bowel Diseases are open now, in 6 countries. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 18–64
Pontificia Universidad Catolica de Chile · Sites in Chile
Ages 18–75
IRCCS Burlo Garofolo · Sites in Italy
Ages 6–17
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
Chinese Medical Association
Ages 18–75
By country, each count listing its studies:
Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 3 · Phase 4 10
First in 2006; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 275 is above the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 83 across the 20 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies testing infliximab in Inflammatory Bowel Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06758024Pontificia Universidad Catolica de ChilePROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel Disease | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing infliximab in Inflammatory Bowel Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about the treatment with subcutaneous infliximab in patients with inflammatory bowel disease (IBD) that were previously treated with an optimized dose of intravenous infliximab.
The main question it aims to answer is:
Participants will switch from intravenous infliximab to subcutaneous infliximab and will be randomized to the intervention arm (Subcutaneous infliximab weekly) or the interventional comparison arm (subcutaneous infliximab bi-weekly). Participants will follow daily clinical practice in the monitoring for clinical and biological remission.
The participants that are willing to switch to subcutaneous infliximab will be compared to a group of participants not willing to switch. These participants will continue to be treated with their optimized intravenous dose of infliximab.
Inflammatory bowel diseases (IBD) are a group of immune mediated disorders primarily targeting the gastro-intestinal tract and consist of two distinct phenotypes: Crohn's disease (CD) and ulcerative colitis (UC) that share similarities in both clinical presentation, pathophysiology and treatment. A small proportion of IBD patients cannot be correctly characterized in one of those categories and is referred to as IBD type unclassified (IBDU), which is often classified under UC for clinical research purposes. TNF inhibitors are one of the most frequently prescribed biological therapies and remain an important part of the therapeutic arsenal with international guidelines recommending their use in moderate-to-severe CD and UC when conventional treatments have failed.
Infliximab, a chimer monoclonal antibody against tumor necrosis factor (TNF), was the first anti-TNF agent to be approved for treating IBD as early as 1999. After losing its product patent in 2013, several biosimilars of infliximab have been commercialized including CT-P13. Originally only available in an intravenous (IV) formulation, a subcutaneous (SC) formulation of CT-P13 has been registered for treating moderate-to-severe CD and UC as well. However, many questions on the use of these subcutaneous formulations of infliximab in daily clinical practice remain unanswered, especially in patients who previously required IV dose optimization of infliximab.
The primary objective of the AMARETTO trial is to compare clinical and biological outcome between a regimen with SC infliximab every week and SC infliximab every other week among patients who were in clinical and biological remission with an optimized IV schedule when they switched to SC infliximab.
The secondary objectives of this study are:
This study is a national, multicenter, randomized, open-label, prospective, pragmatic trial in Belgium. The trial design is as follows:
NOTE: patients that switch to subcutaneous infliximab will be asked to collect all at home administrations in a diary and to additionnaly answer a questionnaire about the satisfaction of switching to subcutaneous infliximab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will switch from an optimized dose of intravenous infliximab to an optimized dose of subcutaneous infliximab. This means the participants will inject 120 mg subcutaneous infliximab every week.
Drug: Infliximab
Participants will switch from an optimized dose of intravenous infliximab to subcutaneous infliximab. This means the participants will inject 120 mg subcutaneous infliximab every other week.
Drug: Infliximab
Participants not willing to switch will continue treatment with intravenous infliximab at the same dosing schedule as before.
Drug: Infliximab
Weekly administration of subcutaneous infliximab.
Bi-weekly administration of subcutaneous infliximab.
Optimized dosing schedule of intravenous infliximab.
• The proportion of patients that maintain steroid-free clinical and biological remission by week 52 without treatment optimization after switch to SC infliximab (composite endpoint)
Time frame: week 52
• The proportion of patients that maintain steroid-free clinical and biological remission by week 52 with treatment optimization
Time frame: week 52
• The proportion of patients that maintain steroid-free clinical and biological remission by week 52 (with or without treatment optimization)
Time frame: week 52
• The proportion of patients that maintain steroid-free clinical and biological remission by week 8, by week 24 (without treatment optimization)
Time frame: week 8 and week 24
• The proportion of patients that maintain steroid-free clinical remission by week 8, by week 24, by week 52 (without treatment optimization)
Time frame: week 8, week 24 and week 54
• The proportion of patients that maintain steroid-free biological remission by week 8, by week 24, by week 52 (without treatment optimization)
Time frame: week 8, week 24 and week 52
• The proportion of patients switching back to IV infliximab by week 8, by week 24, by week 52
Time frame: week 6, week 24 and week 52
• Time to an objectified clinical relapse
Time frame: over 52 weeks
• Time to treatment optimization
Time frame: over 52 weeks
• Time to treatment discontinuation
Time frame: over 52 weeks
• Patients experience and satisfaction score with switching to SC therapy by week 8, week 24 and by week 52.
Patients who switched to subcutaneous infliximab will be asked to answer a satisfaction questionnaire about the subcutaneous administration at each on site visit. This questionnaire involves questions whit answers on a scale from 1 to 10.
Time frame: week 8, week 24 and week 52
• The proportion of eligible patients willing to switch and effectively switching to SC therapy
Time frame: week 0
• Identification of reasons for willing or not willing to switch to SC therapy
During the inclusion visit, patients will be asked why they are willing or not willing to switch to SC infliximab. This is a descriptive outcome.
Time frame: week 0
• Identification of reasons for treatment optimization (clinical disease activity, biological disease activity, endoscopic disease activity, radiological disease activity, and/or other)
During the study, it is possible that the patient will need a treatment optimization as sometimes needed in standard of care. The number of patients needing a treatment optimization will be checked as well as the reason for this treatment optimization (descriptive)
Time frame: over 52 weeks
• Identification of reasons for treatment discontinuation (clinical disease activity, biological disease activity, endoscopic disease activity, radiological disease activity, adverse events, pregnancy, patient's request, and/or other)
During the study, it is possible that the patient will need to discontinue the infliximab treatment as sometimes needed in standard of care. The number of patients undergoing a treatment discontinuation will be checked as well as the reason for this treatment discontinuation (descriptive)
Time frame: over 52 weeks
• The number and type of (serious) adverse events by week 52 or 54
Time frame: week 52
The association of infliximab trough level and antibody level (if available) at screening to the maintenance of clinical and biological remission after switch to SC infliximab.
Time frame: Between week 0 and week 52
The association of the IV dosing schedule to the maintenance of clinical and biological remission after switch to SC infliximab.
Time frame: Between week 0 and week 52
The total cost of infliximab therapy
Time frame: Between week 0 and week 52
The quality-adjusted life years
Time frame: Between week 0 and week 52
The total cost to quality-adjusted life year ratio
Time frame: Between week 0 and week 52
Plan to share: No
Started Apr 2024 (actual). Primary completion is estimated for May 2026, 25 months after the start.
Of 33 non-industry phase 4 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 63. This study's planned 25 months is below that.
Counting every sponsor, half of 38 studies reached it within 38 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infliximab
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW